A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients with Triple Negative Breast Cancer That Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Brief description of study

This is a large global study for people with a type of breast cancer called triple-negative breast cancer (TNBC). It's happening in many hospitals worldwide. The study focuses on patients who had surgery after receiving chemotherapy for their cancer but still have signs of cancer in their breast or armpit. Before joining, they must have had all visible cancer removed and, if needed, radiation therapy. Around 1514 patients will participate in this research. To be eligible, patients must have TNBC, which will be determined by certain medical guidelines. Their cancer cells should not have specific receptors. If patients have a different type of breast cancer or certain genetic changes, they can't be part of the study. The research will compare two groups: one group will receive a medicine called "Sacituzumab Govitecan" and another called "Pembrolizumab," while the other group will get a treatment chosen by their doctor. The study will last for up to 8 treatment cycles, or until the cancer returns, or if it becomes too challenging for the patient, or for other reasons such as the patient's choice to stop. Even after treatment ends, patients will be followed for an extended period to monitor their progress and see if the cancer comes back or if they are doing well.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.